参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Esophageal and Esophagogastric Junction Cancers Version1.2019 — March 14, 2019.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Shi C, Berlin J, Branton P, et al.Protocol for the examination of specimens from patients with carcinoma of the esophagus.CAP Cancer Protocols 2017: 1-17.olders/WebContent/pdf/esophagus-13protocol-311 2.pdf.
4.Healy MA, Yin H, Reddy RM, et al.Use of positron emission tomography to detect recurrence and associations with survival in patients with lung and esophageal cancers.J Natl Cancer Inst 2016, 108.
5.Bartley AN, Washington MK, Colasacco C, et al.HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.J Clin Oncol 2017, 35: 446-464.
6.U.S.Food and Drug Administration.FDA grants accelerated approval to pembrolizumab for advanced gastric cancer.2017.
7.Luketich JD, Pennathur A, Franchetti Y, et al.Minimally invasive esophagectomy: results of a prospective phase II multicenter trial-the eastern cooperative oncology group(E2202)study.Ann Surg 2015, 261: 702-707.
8.Tirumani H, Rosenthal MH, Tirumani SH, et al.Esophageal carcinoma: current concepts in the role of imaging in staging and management.Can Assoc Radiol J 2015, 66: 130-139.
9.Koen Talsma A, Shapiro J, Looman CW, et al.Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.Ann Surg 2014, 260: 786-792.
10.Leggett CL, Lewis JT, Wu TT, et al.Clinical and histologic determinants of mortality for patients with Barrett’s esophagus-related T1 esophageal adenocarcinoma.Clin Gastroenterol Hepatol 2015, 13: 658-664.(https://www.daowen.com)
11.Wang J, Palmer M, Bilton SD, et al.Comparing proton beam to intensity modulated radiation therapy planning in esophageal cancer.Int J Part Ther 2015, 1: 866-877.
12.Warren S, Partridge M, Bolsi A, et al.An analysis of plan robustness for esophageal tumors: comparing volumetric modulated arc therapy plans and spot scanning proton planning.Int J Radiat Oncol Biol Phys 2016, 95: 199-207.
13.Shapiro J, van Lanschot JJB, Hulshof M, et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS): long-term results of a randomised controlled trial.Lancet Oncol 2015, 16: 1090-1098.
14.Vellayappan BA, Soon YY, Ku GY, et al.Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.Cochrane Database Syst Rev 2017, 8: CD010511.
15.Messager M, Mirabel X, Tresch E, et al.Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid(FOLFOX)for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.BMC Cancer 2016, 16: 318.
16.Van Cutsem E, Boni C, Tabernero J, et al.Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.Ann Oncol 2015, 26: 149-156.
17.Fuchs CS, Tomasek J, Yong CJ, et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet 2014, 383: 31-39.
18.Liang J, E M, Wu G, et al.Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.Onco Targets Ther 2013, 6: 1589-1596.
19.Shah MA, Cho JY, Tan IB, et al.A randomized phase IIstudy of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction.Oncologist 2016, 21: 1085-1090.
20.Shah MA, Bang YJ, Lordick F, et al.Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, METpositive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial.JAMA Oncol 2017, 3: 620-627.